A citation-based method for searching scientific literature

Thomas Graillon, Marc Sanson, Chantal Campello, Ahmed Idbaih, Matthieu Peyre, Hadrien Peyrière, Noémie Basset, Didier Autran, Catherine Roche, Michel Kalamarides, Pierre-Hugues Roche, Stéphane Fuentes, Emeline Tabouret, Maryline Barrie, Anita Cohen, Stéphane Honoré, Mohamed Boucekine, Karine Baumstarck, Dominique Figarella-Branger, Anne Barlier, Henry Dufour, Olivier Louis Chinot. Clin Cancer Res 2020
Times Cited: 39







List of co-cited articles
406 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis.
Felix Sahm, Daniel Schrimpf, Damian Stichel, David T W Jones, Thomas Hielscher, Sebastian Schefzyk, Konstantin Okonechnikov, Christian Koelsche, David E Reuss, David Capper,[...]. Lancet Oncol 2017
330
51

Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma.
Thomas J Kaley, Patrick Wen, David Schiff, Keith Ligon, Sam Haidar, Sasan Karimi, Andrew B Lassman, Craig P Nolan, Lisa M DeAngelis, Igor Gavrilovic,[...]. Neuro Oncol 2015
143
48

The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.
David N Louis, Arie Perry, Guido Reifenberger, Andreas von Deimling, Dominique Figarella-Branger, Webster K Cavenee, Hiroko Ohgaki, Otmar D Wiestler, Paul Kleihues, David W Ellison. Acta Neuropathol 2016
48

Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO.
Victoria E Clark, E Zeynep Erson-Omay, Akdes Serin, Jun Yin, Justin Cotney, Koray Ozduman, Timuçin Avşar, Jie Li, Phillip B Murray, Octavian Henegariu,[...]. Science 2013
486
48

EANO guidelines for the diagnosis and treatment of meningiomas.
Roland Goldbrunner, Giuseppe Minniti, Matthias Preusser, Michael D Jenkinson, Kita Sallabanda, Emmanuel Houdart, Andreas von Deimling, Pantelis Stavrinou, Florence Lefranc, Morten Lund-Johansen,[...]. Lancet Oncol 2016
377
46

A phase II trial of bevacizumab and everolimus as treatment for patients with refractory, progressive intracranial meningioma.
Kent C Shih, Sajeel Chowdhary, Paul Rosenblatt, Alva B Weir, Gregg C Shepard, Jeffrey T Williams, Mythili Shastry, Howard A Burris, John D Hainsworth. J Neurooncol 2016
50
43

Atypical and anaplastic meningiomas treated with bevacizumab.
Lakshmi Nayak, Fabio M Iwamoto, Jeremy D Rudnick, Andrew D Norden, Eudocia Quant Lee, Jan Drappatz, Antonio Omuro, Thomas J Kaley. J Neurooncol 2012
110
43

Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations.
Priscilla K Brastianos, Peleg M Horowitz, Sandro Santagata, Robert T Jones, Aaron McKenna, Gad Getz, Keith L Ligon, Emanuele Palescandolo, Paul Van Hummelen, Matthew D Ducar,[...]. Nat Genet 2013
377
41

Historical benchmarks for medical therapy trials in surgery- and radiation-refractory meningioma: a RANO review.
Thomas Kaley, Igor Barani, Marc Chamberlain, Michael McDermott, Katherine Panageas, Jeffrey Raizer, Leland Rogers, David Schiff, Michael Vogelbaum, Damien Weber,[...]. Neuro Oncol 2014
125
38

Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series.
Emil Lou, Ashley L Sumrall, Scott Turner, Katherine B Peters, Annick Desjardins, James J Vredenburgh, Roger E McLendon, James E Herndon, Frances McSherry, Julie Norfleet,[...]. J Neurooncol 2012
114
38

Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma.
Malak Abedalthagafi, Wenya Linda Bi, Ayal A Aizer, Parker H Merrill, Ryan Brewster, Pankaj K Agarwalla, Marc L Listewnik, Dora Dias-Santagata, Aaron R Thorner, Paul Van Hummelen,[...]. Neuro Oncol 2016
148
38

TERT Promoter Mutations and Risk of Recurrence in Meningioma.
Felix Sahm, Daniel Schrimpf, Adriana Olar, Christian Koelsche, David Reuss, Juliane Bissel, Annekathrin Kratz, David Capper, Sebastian Schefzyk, Thomas Hielscher,[...]. J Natl Cancer Inst 2015
188
38

Recurrent somatic mutations in POLR2A define a distinct subset of meningiomas.
Victoria E Clark, Akdes Serin Harmancı, Hanwen Bai, Mark W Youngblood, Tong Ihn Lee, Jacob F Baranoski, A Gulhan Ercan-Sencicek, Brian J Abraham, Abraham S Weintraub, Denes Hnisz,[...]. Nat Genet 2016
171
33

DNA methylation profiling to predict recurrence risk in meningioma: development and validation of a nomogram to optimize clinical management.
Farshad Nassiri, Yasin Mamatjan, Suganth Suppiah, Jetan H Badhiwala, Sheila Mansouri, Shirin Karimi, Olli Saarela, Laila Poisson, Irina Gepfner-Tuma, Jens Schittenhelm,[...]. Neuro Oncol 2019
83
33

Germline and somatic BAP1 mutations in high-grade rhabdoid meningiomas.
Ganesh M Shankar, Malak Abedalthagafi, Rachael A Vaubel, Parker H Merrill, Naema Nayyar, Corey M Gill, Ryan Brewster, Wenya Linda Bi, Pankaj K Agarwalla, Aaron R Thorner,[...]. Neuro Oncol 2017
67
30

Genomic landscape of high-grade meningiomas.
Wenya Linda Bi, Noah F Greenwald, Malak Abedalthagafi, Jeremiah Wala, Will J Gibson, Pankaj K Agarwalla, Peleg Horowitz, Steven E Schumacher, Ekaterina Esaulova, Yu Mei,[...]. NPJ Genom Med 2017
85
30

Double-Blind Phase III Randomized Trial of the Antiprogestin Agent Mifepristone in the Treatment of Unresectable Meningioma: SWOG S9005.
Yongli Ji, Cathryn Rankin, Steven Grunberg, Andy E Sherrod, Jamshid Ahmadi, Jeannette J Townsend, Lynn G Feun, Ruth K Fredericks, Christy A Russell, Fairooz F Kabbinavar,[...]. J Clin Oncol 2015
65
30

Evidence for the complete inactivation of the NF2 gene in the majority of sporadic meningiomas.
M H Ruttledge, J Sarrazin, S Rangaratnam, C M Phelan, E Twist, P Merel, O Delattre, G Thomas, M Nordenskjöld, V P Collins. Nat Genet 1994
443
28

BAP1 mutations in high-grade meningioma: implications for patient care.
Ganesh M Shankar, Sandro Santagata. Neuro Oncol 2017
80
28

mTORC1 inhibitors suppress meningioma growth in mouse models.
Doreen Pachow, Nadine Andrae, Nadine Kliese, Frank Angenstein, Oliver Stork, Annette Wilisch-Neumann, Elmar Kirches, Christian Mawrin. Clin Cancer Res 2013
68
28


Meningiomas: knowledge base, treatment outcomes, and uncertainties. A RANO review.
Leland Rogers, Igor Barani, Marc Chamberlain, Thomas J Kaley, Michael McDermott, Jeffrey Raizer, David Schiff, Damien C Weber, Patrick Y Wen, Michael A Vogelbaum. J Neurosurg 2015
304
25

High incidence of activating TERT promoter mutations in meningiomas undergoing malignant progression.
Stéphane Goutagny, Jean C Nault, Maxime Mallet, Dominique Henin, Jessica Z Rossi, Michel Kalamarides. Brain Pathol 2014
158
25

Advances in meningioma genetics: novel therapeutic opportunities.
Matthias Preusser, Priscilla K Brastianos, Christian Mawrin. Nat Rev Neurol 2018
78
25

A phase II trial of PTK787/ZK 222584 in recurrent or progressive radiation and surgery refractory meningiomas.
Jeffrey J Raizer, Sean A Grimm, Alfred Rademaker, James P Chandler, Kenji Muro, Irene Helenowski, Laurie Rice, Katie McCarthy, Sandra K Johnston, Maciej M Mrugala,[...]. J Neurooncol 2014
61
25

Recurrent meningioma: salvage therapy with long-acting somatostatin analogue.
Marc C Chamberlain, Michael J Glantz, Camilo E Fadul. Neurology 2007
120
23

NF2/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth.
Marianne F James, Sangyeul Han, Carolyn Polizzano, Scott R Plotkin, Brendan D Manning, Anat O Stemmer-Rachamimov, James F Gusella, Vijaya Ramesh. Mol Cell Biol 2009
185
23

SMO mutation status defines a distinct and frequent molecular subgroup in olfactory groove meningiomas.
Julien Boetto, Franck Bielle, Marc Sanson, Matthieu Peyre, Michel Kalamarides. Neuro Oncol 2017
51
23

Frequent AKT1E17K mutations in skull base meningiomas are associated with mTOR and ERK1/2 activation and reduced time to tumor recurrence.
Ümmügülsüm Yesilöz, Elmar Kirches, Christian Hartmann, Johannes Scholz, Siegfried Kropf, Felix Sahm, Makoto Nakamura, Christian Mawrin. Neuro Oncol 2017
47
23

Secretory meningiomas are defined by combined KLF4 K409Q and TRAF7 mutations.
David E Reuss, Rosario M Piro, David T W Jones, Matthias Simon, Ralf Ketter, Marcel Kool, Albert Becker, Felix Sahm, Stefan Pusch, Jochen Meyer,[...]. Acta Neuropathol 2013
146
23

Proposed response assessment and endpoints for meningioma clinical trials: report from the Response Assessment in Neuro-Oncology Working Group.
Raymond Y Huang, Wenya Linda Bi, Michael Weller, Thomas Kaley, Jaishri Blakeley, Ian Dunn, Evanthia Galanis, Matthias Preusser, Michael McDermott, Leland Rogers,[...]. Neuro Oncol 2019
55
20

CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012-2016.
Quinn T Ostrom, Gino Cioffi, Haley Gittleman, Nirav Patil, Kristin Waite, Carol Kruchko, Jill S Barnholtz-Sloan. Neuro Oncol 2019
894
20

Global epigenetic profiling identifies methylation subgroups associated with recurrence-free survival in meningioma.
Adriana Olar, Khalida M Wani, Charmaine D Wilson, Gelareh Zadeh, Franco DeMonte, David T W Jones, Stefan M Pfister, Erik P Sulman, Kenneth D Aldape. Acta Neuropathol 2017
71
20

Integrated genomic analyses of de novo pathways underlying atypical meningiomas.
Akdes Serin Harmancı, Mark W Youngblood, Victoria E Clark, Süleyman Coşkun, Octavian Henegariu, Daniel Duran, E Zeynep Erson-Omay, Leon D Kaulen, Tong Ihn Lee, Brian J Abraham,[...]. Nat Commun 2017
91
20

Octreotide therapy in meningiomas: in vitro study, clinical correlation, and literature review.
Thomas Graillon, David Romano, Céline Defilles, Alexandru Saveanu, Amira Mohamed, Dominique Figarella-Branger, Pierre-Hugues Roche, Stéphane Fuentes, Olivier Chinot, Henry Dufour,[...]. J Neurosurg 2017
27
25

Durable Control of Metastatic AKT1-Mutant WHO Grade 1 Meningothelial Meningioma by the AKT Inhibitor, AZD5363.
Michael Weller, Patrick Roth, Felix Sahm, Isabel Burghardt, Bernhard Schuknecht, Elisabeth J Rushing, Luca Regli, Justin P Lindemann, Andreas von Deimling. J Natl Cancer Inst 2017
28
25

Molecular and translational advances in meningiomas.
Suganth Suppiah, Farshad Nassiri, Wenya Linda Bi, Ian F Dunn, Clemens Oliver Hanemann, Craig M Horbinski, Rintaro Hashizume, Charles David James, Christian Mawrin, Houtan Noushmehr,[...]. Neuro Oncol 2019
41
17

Loss of histone H3K27me3 identifies a subset of meningiomas with increased risk of recurrence.
Leah M Katz, Thomas Hielscher, Benjamin Liechty, Joshua Silverman, David Zagzag, Rajeev Sen, Peter Wu, John G Golfinos, David Reuss, Marian Christoph Neidert,[...]. Acta Neuropathol 2018
64
17

Somatostatin receptor-targeted radionuclide therapy for progressive meningioma: benefit linked to 68Ga-DOTATATE/-TOC uptake.
Katharina Seystahl, Veit Stoecklein, Ulrich Schüller, Elisabeth Rushing, Guillaume Nicolas, Niklaus Schäfer, Harun Ilhan, Athina Pangalu, Michael Weller, Jörg-Christian Tonn,[...]. Neuro Oncol 2016
56
17

Analysis of CDKN2A gene alterations in recurrent and non-recurrent meningioma.
Anne Guyot, Mathilde Duchesne, Sandrine Robert, Anne-Sophie Lia, Paco Derouault, Erwan Scaon, Leslie Lemnos, Henri Salle, Karine Durand, François Labrousse. J Neurooncol 2019
16
43

DMD genomic deletions characterize a subset of progressive/higher-grade meningiomas with poor outcome.
Tareq A Juratli, Devin McCabe, Naema Nayyar, Erik A Williams, Ian M Silverman, Shilpa S Tummala, Alexandria L Fink, Aymen Baig, Maria Martinez-Lage, Martin K Selig,[...]. Acta Neuropathol 2018
40
17

Intermediate-risk meningioma: initial outcomes from NRG Oncology RTOG 0539.
Leland Rogers, Peixin Zhang, Michael A Vogelbaum, Arie Perry, Lynn S Ashby, Jignesh M Modi, Anthony M Alleman, James Galvin, David Brachman, Joseph M Jenrette,[...]. J Neurosurg 2018
110
17

Epidemiology and etiology of meningioma.
Joseph Wiemels, Margaret Wrensch, Elizabeth B Claus. J Neurooncol 2010
585
17

CDKN2A/B homozygous deletion is associated with early recurrence in meningiomas.
Philipp Sievers, Thomas Hielscher, Daniel Schrimpf, Damian Stichel, David E Reuss, Anna S Berghoff, Marian C Neidert, Hans-Georg Wirsching, Christian Mawrin, Ralf Ketter,[...]. Acta Neuropathol 2020
32
21

Temozolomide for treatment-resistant recurrent meningioma.
Marc C Chamberlain, Denice D Tsao-Wei, Susan Groshen. Neurology 2004
101
17



Recurrent high-grade meningioma: a phase II trial with somatostatin analogue therapy.
Marta Simó, Andreas A Argyriou, Miquel Macià, Gerard Plans, Carles Majós, Noemi Vidal, Miguel Gil, Jordi Bruna. Cancer Chemother Pharmacol 2014
40
15

Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma.
Andrew D Norden, Keith L Ligon, Samantha N Hammond, Alona Muzikansky, David A Reardon, Thomas J Kaley, Tracy T Batchelor, Scott R Plotkin, Jeffrey J Raizer, Eric T Wong,[...]. Neurology 2015
51
15

Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08).
Patrick Y Wen, W K Alfred Yung, Kathleen R Lamborn, Andrew D Norden, Timothy F Cloughesy, Lauren E Abrey, Howard A Fine, Susan M Chang, H Ian Robins, Karen Fink,[...]. Neuro Oncol 2009
90
15


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.